Swiss Covagen bags $47m in series B
This article was originally published in Scrip
The Swiss company Covagen, whose lead program aims to beat the performance of antibody TNF inhibitors in inflammatory diseases by adding anti-IL17 activity to the market-leading drug, has secured CHF42m ($47m) in a series B financing. It has yet to begin trials in man of its bispecific "FynomAbs" (binding proteins fused to antibodies), but hopes to enter the clinic next year.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.